Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Sickle Cell Pain and Inflammation
NCT06930703Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in sickle cell disease (SCD) (4 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Tumor Necrosis Factor-alpha level at 4 weeks. Started Apr 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06930703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930703.